申请人:Mitsui Toatsu Kagaku Kabushiki Kaisha
公开号:US04521415A1
公开(公告)日:1985-06-04
6-(Substituted phenyl)-4,5-dihydro-3(2H)-pyridazinone compounds possessing strong platelet aggregation inhibiting activity and blood pressure depressing activity, having the general formula: ##STR1## wherein R.sup.1 is hydrogen or lower alkyl; R.sup.2 is hydrogen, lower alkyl, lower alkylthio or the grouping R.sup.5 --NH-- where R.sup.5 is lower alkyl; R.sup.3 is phenyl, pyridyl, benzyl, lower alkyl or a substituted phenyl group carrying at any desired position on the benzene ring thereof the grouping: ##STR2## where R.sup.1 has the same meaning as given above; R.sup.4 is hydrogen or halogen; n is 0 or 1; and when both R.sup.2 and R.sup.3 are lower alkyl groups, R.sup.2 and R.sup.3 may be combined together with the bridging member ##STR3## where m is 2 or 3, as well as physiologically acceptable acid-addition salts thereof, and processes for preparing them.
具有强烈抑制血小板聚集活性和降低血压活性的6-(取代苯基)-4,5-二氢-3(2H)-吡啶酮化合物,具有通用结构式: 其中R.sup.1为氢或较低烷基; R.sup.2为氢、较低烷基、较低烷硫基或基团R.sup.5 --NH--,其中R.sup.5为较低烷基; R.sup.3为苯基、吡啶基、苄基、较低烷基或在苯环上的任意位置携带取代苯基团的结构: 其中R.sup.1具有上述相同含义; R.sup.4为氢或卤素; n为0或1; 当R.sup.2和R.sup.3均为较低烷基基团时,R.sup.2和R.sup.3可以与桥接成员结合在一起,其中m为2或3,以及其生理上可接受的酸加盐,以及其制备方法。